What is NDC 50881-006?

50881-006 is the product NDC for Zynyz (retifanlimab-dlwr), Retifanlimab 25 mg/mL injection, listed with the FDA by Incyte Corporation. It has 1 package NDC, shown above in 10- and 11-digit form.

Incyte Corporation, NDC labeler code 50881. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Zynyz?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Zynyz NDC 50881-006 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50881-006Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50881-0006Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50881-006-03	50881000603	1 VIAL, SINGLE-USE in 1 CARTON (50881-006-03) / 20 mL in 1 VIAL, SINGLE-USEMarketed from Mar 22, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zynyz
Generic name (nonproprietary): retifanlimab-dlwr
Active ingredients: Retifanlimab — 25 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Incyte CorporationNDC labeler code 50881
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761334
Marketing start: Mar 22, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Programmed Death Receptor-1-directed Antibody Interactions (Mechanism)
Identifiers: Product ID 50881-006_232fcac8-b438-4872-8ef1-6332ecdf9304SPL ID 232fcac8-b438-4872-8ef1-6332ecdf9304
Pharmacologic class: Programmed Death Receptor-1 Blocking Antibody

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N450881000603 followed by a unit qualifier and the quantity

Package 50881-0006-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 50881-006

What is NDC 50881-006?: 50881-006 is the product NDC for Zynyz (retifanlimab-dlwr), Retifanlimab 25 mg/mL injection, listed with the FDA by Incyte Corporation. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Zynyz (Retifanlimab-dlwr).
What is the active ingredient?: Retifanlimab.
Who is the labeler?: Incyte Corporation, NDC labeler code 50881. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Zynyz?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Zynyz (Retifanlimab-dlwr) NDC 50881-006